Full Breakdown
NHS England Makes Fampridine Available for People with Multiple Sclerosis
7/23/2026, 10:51:53 AM
Core Event – First NHS Access to a Walking-Aid Pill
The NHS in England has begun prescribing fampridine, the first drug specifically approved to improve walking ability in people with multiple sclerosis (MS). Up to 5,000 patients a year are expected to be eligible, based on the severity of their walking difficulties. Patients will start with a two- to four-week trial; only those who demonstrate a clear benefit will continue treatment.
Background & Context – From Rejection to Roll-Out
Fampridine had previously been rejected by NHS England on cost-effectiveness grounds, even though it was already funded in Wales, Scotland and Northern Ireland. The new policy reverses that stance, allowing England’s MS population to access the medication through the public health system for the first time.
Data & Statistics – Who Can Benefit and How Effective Is the Drug?
- Eligibility: Adults with an Expanded Disability Status Scale (EDSS) score between 4 (able to walk ~500 m unaided) and 7 (wheelchair-bound or able to walk <=5 m).
- Trial period: 2–4 weeks of twice-daily dosing, with walking ability assessed before and after.
- Potential reach: Approximately 5,000 people per year, out of more than 120,000 people living with MS in England.
- Efficacy in trials: Around 40 %–43 % of participants showed improved walking speed and endurance.
- Continuation: Only patients who show “clear benefit” after the trial will remain on the medication.
Official Statements & Responses – NHS and Advocacy Perspectives
Prof Frankie Swords, NHS national medical director, emphasized that even modest improvements in walking can enhance daily independence for thousands of patients. Ceri Smith, head of policy and evidence at the MS Society, described the approval as “life-changing,” noting the potential for patients to maintain employment and greater autonomy.
On-the-Ground Reports – Patient Experience
Aysen Slack, a 65-year-old resident of Eastbourne, previously paid for fampridine privately until the cost became prohibitive. She reported that the drug “was working well for me” before she stopped, and that her mobility had since declined to the point where she now relies on walking sticks. Slack said the NHS decision would make a “huge difference” to her life and expressed eagerness to restart the treatment.
Verbatim Quotes
- “Walking difficulties can have a huge impact on the freedom and independence of people with MS, so this signal-boosting pill could be life-changing for thousands of patients.” — Frankie Swords, professor
- “I would definitely like to try fampridine again on the NHS. My mobility has decreased a lot and even in my flat I have to use sticks now. It would make a huge difference to my life if I were able to improve my walking.” — Ceri Smith
Why It Matters – Potential Impact on Quality of Life
By providing a pharmacological option that directly boosts nerve signal transmission, the NHS rollout could reduce reliance on physiotherapy and walking aids for a subset of MS patients. Improved mobility may translate into greater social participation, reduced need for personal care, and the ability to stay in work, thereby lessening the broader socioeconomic burden of MS.
